PL2379600T3 - Przeciwciała przeciwko inhibitorowi szlaku czynnika tkankowego - Google Patents

Przeciwciała przeciwko inhibitorowi szlaku czynnika tkankowego

Info

Publication number
PL2379600T3
PL2379600T3 PL09793543T PL09793543T PL2379600T3 PL 2379600 T3 PL2379600 T3 PL 2379600T3 PL 09793543 T PL09793543 T PL 09793543T PL 09793543 T PL09793543 T PL 09793543T PL 2379600 T3 PL2379600 T3 PL 2379600T3
Authority
PL
Poland
Prior art keywords
antibodies against
tissue factor
pathway inhibitor
against tissue
factor pathway
Prior art date
Application number
PL09793543T
Other languages
English (en)
Other versions
PL2379600T5 (pl
Inventor
Ida Hilden
Berit Olsen Krogh
Jes Thorn Clausen
Ole Hvilsted Olsen
Jens Breinholt
Brian Lauritzen
Brit Binow Sørensen
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40639722&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2379600(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of PL2379600T3 publication Critical patent/PL2379600T3/pl
Publication of PL2379600T5 publication Critical patent/PL2379600T5/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/38—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL09793543T 2008-12-22 2009-12-18 Przeciwciała przeciwko inhibitorowi szlaku czynnika tkankowego PL2379600T5 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08172520 2008-12-22
EP09793543.1A EP2379600B2 (en) 2008-12-22 2009-12-18 Antibodies against tissue factor pathway inhibitor
PCT/EP2009/067598 WO2010072691A1 (en) 2008-12-22 2009-12-18 Antibodies against tissue factor pathway inhibitor

Publications (2)

Publication Number Publication Date
PL2379600T3 true PL2379600T3 (pl) 2014-07-31
PL2379600T5 PL2379600T5 (pl) 2021-03-08

Family

ID=40639722

Family Applications (1)

Application Number Title Priority Date Filing Date
PL09793543T PL2379600T5 (pl) 2008-12-22 2009-12-18 Przeciwciała przeciwko inhibitorowi szlaku czynnika tkankowego

Country Status (23)

Country Link
US (5) US8361469B2 (pl)
EP (3) EP2379600B2 (pl)
JP (2) JP5714505B2 (pl)
KR (2) KR101745394B1 (pl)
CN (1) CN102325795B (pl)
AU (1) AU2009331570C1 (pl)
BR (1) BRPI0924058B1 (pl)
CA (1) CA2745317C (pl)
DK (1) DK2379600T4 (pl)
ES (1) ES2458665T5 (pl)
FI (1) FIC20250014I1 (pl)
FR (2) FR24C1008I1 (pl)
HU (1) HUS2500017I1 (pl)
IL (1) IL213356A (pl)
MX (1) MX2011006501A (pl)
NL (1) NL301310I2 (pl)
NO (1) NO2025013I1 (pl)
PL (1) PL2379600T5 (pl)
PT (1) PT2379600E (pl)
RU (1) RU2562114C2 (pl)
TW (1) TWI476003B (pl)
WO (1) WO2010072691A1 (pl)
ZA (1) ZA201104599B (pl)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2011101969A (ru) 2008-06-30 2012-08-10 Ново Нордиск А/С (DK) Антитела к человеческому интерлейкину-20
UA112050C2 (uk) * 2008-08-04 2016-07-25 БАЄР ХЕЛСКЕР ЛЛСі Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi)
EP2379600B2 (en) 2008-12-22 2020-10-14 Novo Nordisk A/S Antibodies against tissue factor pathway inhibitor
US8454956B2 (en) 2009-08-31 2013-06-04 National Cheng Kung University Methods for treating rheumatoid arthritis and osteoporosis with anti-IL-20 antibodies
BR112012021576A2 (pt) * 2010-02-26 2016-10-25 Novo Nordisk As composições estáveis contendo anticorpo.
HUE047173T2 (hu) 2010-03-01 2020-04-28 Bayer Healthcare Llc Optimalizált monoklonális ellenanyagok szöveti faktor útvonal inhibitor (TFPI) ellen
RU2012153786A (ru) * 2010-05-28 2014-07-10 Ново Нордиск А/С Стабильные многодозовые композиции, содержащие антитело и консервант
JP2013533871A (ja) * 2010-06-30 2013-08-29 ノヴォ ノルディスク アー／エス 組織因子経路インヒビターに特異的に結合することが可能な抗体
US9228022B2 (en) 2010-06-30 2016-01-05 Novo Nordisk A/S Antibodies that are capable of specifically binding tissue factor pathway inhibitor
PE20141149A1 (es) 2011-04-01 2014-08-28 Bayer Healthcare Llc Anticuerpos monoclonales frente al inhibidor de la ruta del factor tisular (tfpi)
US9221904B2 (en) 2012-07-19 2015-12-29 National Cheng Kung University Treatment of osteoarthritis using IL-20 antagonists
US8603470B1 (en) 2012-08-07 2013-12-10 National Cheng Kung University Use of IL-20 antagonists for treating liver diseases
US8852588B2 (en) 2012-08-07 2014-10-07 National Cheng Kung University Treating allergic airway disorders using anti-IL-20 receptor antibodies
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
JP6586016B2 (ja) * 2013-03-15 2019-10-02 ノヴォ ノルディスク アー／エス 組織因子系凝固インヒビター上の２つのエピトープに特異的に結合することが可能な抗体
PL2970497T3 (pl) * 2013-03-15 2018-05-30 Bayer Healthcare Llc Warianty przeciwciał anty-TFPI z różnicowym wiązaniem w zakresie pH dla poprawy farmakokinetyki
CA2906095A1 (en) * 2013-03-15 2014-09-18 Bayer Healthcare Llc Pro-drug antibodies against tissue factor pathway inhibitor
US10457743B2 (en) 2013-07-19 2019-10-29 Novo Nordisk A/S Antibodies recognizing the N-terminal part of tissue factor pathway inhibitor capable of eliciting pro-coagulant activity
CN114621346B (zh) 2013-08-21 2025-06-10 德克萨斯州大学系统董事会 用于靶向连接蛋白半通道的组合物和方法
MY184154A (en) * 2013-12-12 2021-03-23 Shanghai hengrui pharmaceutical co ltd Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
CN106573977B (zh) * 2014-04-27 2020-08-07 菲姆威有限公司 针对ceacam1的人源化抗体
CN106687482B (zh) * 2014-09-17 2022-01-25 诺和诺德股份有限公司 能够结合组织因子途径抑制剂(1-161)上的两个表位的抗体
JP6660957B2 (ja) * 2015-02-25 2020-03-11 モガム インスティチュート フォー バイオメディカル リサーチＭＯＧＡＭ Ｉｎｓｔｉｔｕｔｅ ｆｏｒ Ｂｉｏｍｅｄｉｃａｌ Ｒｅｓｅａｒｃｈ 新規の抗−ｔｆｐｉ抗体及びこれを含む組成物
JP6664467B2 (ja) * 2015-08-19 2020-03-13 ファイザー・インク 組織因子経路インヒビター抗体およびその使用
WO2017147561A1 (en) * 2016-02-26 2017-08-31 The Board Of Regents Of The University Of Texas System CONNEXIN (Cx) 43 HEMICHANNEL-BINDING ANTIBODIES AND USES THEREOF
TWI788321B (zh) 2017-01-20 2023-01-01 美商健臻公司 骨靶向抗體
TW202506185A (zh) 2017-01-20 2025-02-16 法商賽諾菲公司 抗TGF-β抗體及其用途
JP7094722B2 (ja) * 2018-02-28 2022-07-04 キヤノン株式会社 画像読取装置及び画像形成装置
KR102337683B1 (ko) * 2018-09-21 2021-12-13 주식회사 녹십자 고효율 항-tfpi 항체 조성물
BR112021006223A2 (pt) * 2018-10-11 2021-07-06 Pfizer regime de dosagem para antagonistas de inibidor da via de fator tecidual (tfpi)
US20220259290A1 (en) * 2019-07-24 2022-08-18 Japan Science And Technology Agency Innovative production technique for antibody-enzyme
CN112442127A (zh) * 2019-08-29 2021-03-05 苏州康宁杰瑞生物科技有限公司 针对tfpi的单克隆抗体
BR112022007635A2 (pt) * 2019-11-13 2022-07-12 Pfizer Formulação aquosa e estável de anticorpos
EP4177274A4 (en) * 2020-07-02 2024-04-03 Beijing Tuo Jie Biopharmaceutical Co. Ltd. Anti-fxi/fxia antibody, antigen-binding fragment thereof, and pharmaceutical use thereof
EP4216923A1 (en) 2020-09-24 2023-08-02 Novo Nordisk Health Care AG Pharmaceutical formulation of concizumab and method of production thereof
CN116136537A (zh) * 2021-11-16 2023-05-19 北京积水潭医院 组织因子途径抑制物抗凝活性的检测方法和试剂盒及其应用
CN118613492A (zh) * 2022-01-30 2024-09-06 西湖大学 Tfpi结合多肽及其用途

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4966852A (en) † 1987-07-23 1990-10-30 Monsanto Company DNA clone of human tissue factor inhibitor
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
DK261490D0 (da) 1990-10-31 1990-10-31 Novo Nordisk As New pharmaceutical compound
EP0539975A1 (en) † 1991-10-31 1993-05-05 Teijin Limited Method for immunological assay of free lipoprotein-associated coagulation inhibitor (LACI) and kit therefor
JPH06153985A (ja) * 1992-11-16 1994-06-03 Teijin Ltd モノクローナル抗体
JPH06153981A (ja) 1992-11-30 1994-06-03 Teijin Ltd Ｌａｃｉの免疫学的測定方法、それに用いるキット並びにモノクローナル抗体
US5455338A (en) * 1993-11-05 1995-10-03 Zymogenetics, Inc. DNA encoding novel human kunitz-type inhibitors and methods relating thereto
US5589359A (en) 1994-08-05 1996-12-31 Chiron Corporation Chimeric proteins
JPH0875736A (ja) 1994-09-06 1996-03-22 Chemo Sero Therapeut Res Inst ヒト組織因子凝固系インヒビターの定量法
US5902582A (en) * 1995-09-05 1999-05-11 Chiron Corporation Use of TFPI inhibitor for treatment of cancer
JP3681206B2 (ja) 1995-12-26 2005-08-10 株式会社三菱化学ヤトロン 抗ファクターＸａ・ティシュファクターパスウェイインヒビター複合体モノクローナル抗体及びその使用
EP0981548A4 (en) 1997-04-30 2005-11-23 Enzon Inc GLYCOSYLATABLE SINGLE CHAIN ANTIGEN-BINDING PROTEINS, MANUFACTURE AND USE THEREOF
CA2398466A1 (en) * 2000-01-27 2001-08-02 Medimmune, Inc. Ultra high affinity neutralizing antibodies
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
WO2005040219A1 (en) 2003-10-28 2005-05-06 Novo Nordisk A/S Laminin-5 gamma2-binding peptides, related compositions, and use thereof
US7585842B2 (en) 2004-04-16 2009-09-08 The Reagents Of The University Of California Human kunitz-type inhibitor with enhanced antifibrinolytic activity
US7015746B1 (en) * 2004-05-06 2006-03-21 National Semiconductor Corporation Bootstrapped bias mixer with soft start POR
JP2008531692A (ja) † 2005-03-04 2008-08-14 ザ・ボード・オブ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・イリノイ 凝固及び線維素溶解カスケードのモジュレーター
UA112050C2 (uk) * 2008-08-04 2016-07-25 БАЄР ХЕЛСКЕР ЛЛСі Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi)
WO2010071894A2 (en) * 2008-12-19 2010-06-24 Baxter International Inc. Tfpi inhibitors and methods of use
EP2379600B2 (en) 2008-12-22 2020-10-14 Novo Nordisk A/S Antibodies against tissue factor pathway inhibitor
WO2010072687A1 (en) * 2008-12-22 2010-07-01 Novo Nordisk A/S Antibodies against tissue factor pathway inhibitor (tfpi)
US8965454B2 (en) 2009-03-04 2015-02-24 Andrew Llc Amplifier system for cell sites and other suitable applications
US8598327B2 (en) 2009-08-18 2013-12-03 Baxter International Inc. Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics
IN2012DN01984A (pl) 2009-08-18 2015-07-24 Baxter Int
HUE047173T2 (hu) † 2010-03-01 2020-04-28 Bayer Healthcare Llc Optimalizált monoklonális ellenanyagok szöveti faktor útvonal inhibitor (TFPI) ellen
US8598008B2 (en) † 2010-10-20 2013-12-03 Texas Instruments Incorporated Stacked ESD clamp with reduced variation in clamp voltage
WO2012109675A1 (en) † 2011-02-11 2012-08-16 Baxter International Inc. Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics
PE20141149A1 (es) † 2011-04-01 2014-08-28 Bayer Healthcare Llc Anticuerpos monoclonales frente al inhibidor de la ruta del factor tisular (tfpi)
EP2827910A2 (en) † 2012-03-22 2015-01-28 Baxter International Inc Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics
JP6586016B2 (ja) 2013-03-15 2019-10-02 ノヴォ ノルディスク アー／エス 組織因子系凝固インヒビター上の２つのエピトープに特異的に結合することが可能な抗体
JP6660957B2 (ja) † 2015-02-25 2020-03-11 モガム インスティチュート フォー バイオメディカル リサーチＭＯＧＡＭ Ｉｎｓｔｉｔｕｔｅ ｆｏｒ Ｂｉｏｍｅｄｉｃａｌ Ｒｅｓｅａｒｃｈ 新規の抗−ｔｆｐｉ抗体及びこれを含む組成物
JP6664467B2 (ja) † 2015-08-19 2020-03-13 ファイザー・インク 組織因子経路インヒビター抗体およびその使用

Also Published As

Publication number Publication date
EP2379600B1 (en) 2014-01-22
AU2009331570B2 (en) 2013-10-17
FR25C1014I1 (fr) 2025-06-20
EP2746294A3 (en) 2015-01-07
NL301310I2 (nl) 2025-02-11
AU2009331570C1 (en) 2024-04-18
FIC20250014I1 (fi) 2025-03-17
BRPI0924058B1 (pt) 2021-08-17
ZA201104599B (en) 2012-03-28
CN102325795A (zh) 2012-01-18
JP2012513377A (ja) 2012-06-14
IL213356A (en) 2017-06-29
US20110318356A1 (en) 2011-12-29
RU2562114C2 (ru) 2015-09-10
DK2379600T3 (da) 2014-04-28
MX2011006501A (es) 2011-07-12
ES2458665T9 (en) 2025-04-22
EP3260466A1 (en) 2017-12-27
CA2745317A1 (en) 2010-07-01
TW201026330A (en) 2010-07-16
WO2010072691A1 (en) 2010-07-01
JP5714505B2 (ja) 2015-05-07
US20190211112A1 (en) 2019-07-11
RU2011129068A (ru) 2013-01-27
BRPI0924058A2 (pt) 2019-10-15
KR101745394B1 (ko) 2017-06-09
US8361469B2 (en) 2013-01-29
AU2009331570A1 (en) 2011-06-30
FR25C1014I2 (fr) 2026-03-27
JP2015178495A (ja) 2015-10-08
DK2379600T4 (da) 2021-01-04
JP6114326B2 (ja) 2017-04-12
KR101600308B1 (ko) 2016-03-07
US9574011B2 (en) 2017-02-21
EP2379600B2 (en) 2020-10-14
KR20110103432A (ko) 2011-09-20
US8652471B2 (en) 2014-02-18
KR20160031028A (ko) 2016-03-21
EP2379600A1 (en) 2011-10-26
NO2025013I1 (no) 2025-02-25
IL213356A0 (en) 2011-07-31
US20130251722A1 (en) 2013-09-26
CN102325795B (zh) 2015-03-25
HUS2500017I1 (hu) 2025-04-28
PT2379600E (pt) 2014-04-29
TWI476003B (zh) 2015-03-11
EP2746294A2 (en) 2014-06-25
FR24C1008I1 (fr) 2024-04-19
US20130251721A1 (en) 2013-09-26
US20170114147A1 (en) 2017-04-27
ES2458665T5 (es) 2021-06-30
CA2745317C (en) 2019-03-05
PL2379600T5 (pl) 2021-03-08
ES2458665T3 (es) 2014-05-06

Similar Documents

Publication Publication Date Title
HUS2500017I1 (hu) Szöveti faktor bioszintézis út elleni ellenanyagok
IL282658A (en) Monoclonal antibodies against tissue factor pathway inhibitor (TFPI)
SI2949666T1 (sl) Človeška anti alfa-sinukleinska protitelesa
IL211018A0 (en) Novel inhibitors
GB0820117D0 (en) Tourniquet
ZA201102837B (en) Phosphodiestarase inhibitors
GB0714941D0 (en) Inhibitors
HRP20190159T1 (hr) Antitijela humanog anti-alfa-sinukleina
GB201019387D0 (en) Inhibitors
GB0809820D0 (en) Modified tissues
GB0713152D0 (en) Phosphodlesterase inhibitors
GB0816125D0 (en) Novel inhibitors
GB0720364D0 (en) Inhibitor
PH32008000854S1 (en) Tissue
GB0804978D0 (en) Reflection
GB0707488D0 (en) Novel inhibitors
GB0707495D0 (en) Novel inhibitors
GB0707499D0 (en) Novel inhibitors
GB0707632D0 (en) Novel inhibitors
GB0707498D0 (en) Novel inhibitors
GB0704589D0 (en) Novel inhibitors
GB0707493D0 (en) Novel inhibitors
GB0707497D0 (en) Novel inhibitors
GB0803891D0 (en) Glyoxalase inhibitors
GB0803994D0 (en) Pipeline